Randomized Controlled Trials: Randomization and Blinding

By Benn Bluestein-Veyra, M.Sc. Organic Chemistry · Updated 21 October 2026

A randomized controlled trial assigns participants to groups by chance, so the groups differ only by the intervention under study and random variation. Hopewell and colleagues describe well designed and properly executed randomized trials as the most reliable evidence on the benefits of healthcare interventions.^[1]

This reference covers sequence generation, allocation concealment, blinding, design choice, sample size and registration, analysis by assigned group and the CONSORT 2025 statement. Critical appraisal of a trial is possible only when its design, conduct, analysis and results are completely reported, so each feature here can be checked in a published report.^[2]

Randomization balances known and unknown factors between groups

Random assignment gives every participant the same chance of entering each group, which spreads measured and unmeasured characteristics evenly on average. Schulz and Grimes note that anything short of proper randomization invites selection and confounding biases, and they ask investigators to avoid systematic, non-random methods of allocation.^[3]

The groups therefore start alike, and differences in outcome reflect the intervention or chance. Schulz and Grimes recommend reporting baseline comparisons on important prognostic variables and describe hypothesis tests of baseline characteristics as superfluous.^[4]

In a two-arm parallel trial, enrolled participants pass through a concealed allocation step into an intervention group and a comparator group, blinded assessors measure the outcomes, and the analysis keeps each participant in the assigned group (Fig. 1). The CONSORT 2025 checklist and flow diagram ask reports to document each of these steps.^[1][5]

Generating the allocation sequence with simple, block, stratified and minimization methods

The allocation sequence is the list that decides which group each successive participant enters. Schulz and Grimes ask that it come from a random process and that reports describe the method clearly.^[3]

Simple randomization

Simple, or unrestricted, randomization is analogous to repeated fair coin tossing. Schulz and Grimes state that no other approach surpasses it for preventing bias, and that readers should expect and accept the disparities in group size it produces.^[3]

Block and stratified randomization

Blocked randomization restricts the sequence so that group sizes balance at the end of every block; with blocks of four, each block holds two assignments to each group (Fig. 2). Schulz and Grimes advise varying block sizes at random and using larger blocks, particularly in an unblinded trial.^[3]

With a fixed block of four, the last assignment of each block can be deduced once the first three are known, which is why varied block sizes matter.^[3] Stratified randomization prepares a separate sequence within each stratum, such as a recruiting site, and works only when the sequence within each stratum is itself restricted.^[3]

Kahan and Morris showed that balancing groups with stratified blocks or minimization makes the groups correlated. An analysis that ignores the balancing variables gives confidence intervals that are too wide and loses power, while an adjusted analysis gives valid inference.^[6]

Minimization

Minimization assigns each new participant so that predefined factors and group sizes stay as balanced as possible, a method proposed by Taves and by Pocock and Simon. In the simulations reviewed by Scott and colleagues, it produced better balanced groups than restricted or unrestricted randomization and handled more prognostic factors than stratified blocks.^[7]

Scott and colleagues describe minimization as a largely nonrandom method whose assignments can sometimes be predicted with certainty. The review also reports the recommendation that analyses adjust for the minimization factors.^[6][7]

Allocation concealment protects the sequence until each assignment is made

Allocation concealment keeps the clinicians and participants involved in enrollment unaware of upcoming assignments. Schulz and Grimes call it the basis of proper randomization, since without it even a properly generated sequence can be subverted by anyone who deciphers it.^[4]

Concealment acts up to the moment of assignment, and blinding acts afterward, during delivery of the interventions, measurement and analysis. Schulz and Grimes report that many medical researchers confuse the two, a confusion that indicates misunderstanding of both.^[8]

Common mechanisms are a central randomization service contacted after enrollment and sequentially numbered, opaque, sealed envelopes, and a report should name the mechanism used.^[2][4] The concealment step sits between enrollment and the two groups in a parallel trial (Fig. 1).^[4]

Concealment and effect size

In a 1995 study, Schulz and colleagues analyzed 250 controlled trials from 33 meta-analyses. Compared with adequately concealed trials, odds ratios were exaggerated by 41% in trials with inadequate concealment and by 30% in trials with unclear concealment.^[9]

Savović and colleagues later combined 1,973 trials from seven meta-epidemiological studies and found exaggerated effect estimates with inadequate or unclear sequence generation and concealment, driven mainly by subjectively assessed outcomes.^[10] A systematic review of 24 meta-epidemiological studies by Page and colleagues reached a similar conclusion.^[11]

Blinding works best when each blinded group is named

Blinding keeps trial participants, investigators or outcome assessors unaware of the assigned intervention so that the knowledge cannot influence them. Schulz and Grimes explain that it reduces differential assessment of outcomes and can also improve adherence and retention and limit co-intervention.^[8]

Four groups that can be blinded

• Participants, whose adherence and retention blinding can support.^[8]
• Clinicians and other care providers, whose knowledge of the assignment can lead to supplemental care, called co-intervention.^[8]
• Outcome assessors, the people who collect or adjudicate outcome data.^[8]
• Data analysts, one of the six groups Devereaux and colleagues listed when asking physicians what blinding terms mean.^[12]

Why "double blind" needs a definition

Devereaux and colleagues surveyed 91 physicians and 25 textbooks and found 17 physician interpretations and nine textbook definitions of double blinding. They concluded that explicit statements about the blinding status of each group should replace the ambiguous terms.^[12]

Schulz and Grimes ask reports to state who was blinded and how. They recommend placing greater credence in results when at least the outcome assessment was blinded, with objective outcomes leaving little room for bias.^[8]

What meta-epidemiological studies report about blinding

Hróbjartsson and colleagues reviewed 21 trials that assessed the same binary outcome with both blinded and non-blinded assessors. Non-blinded assessors exaggerated odds ratios by 36% on average.^[13]

In the MetaBLIND study of 1,153 trials, Moustgaard and colleagues found no evidence of an average difference in estimated effects by blinding status. The authors suggested replication and advised that blinding remain a methodological safeguard in trials.^[14]

Parallel, crossover, factorial, cluster and split-body designs suit different questions

Most trials use a parallel group design, in which each participant receives one intervention and the groups are compared with each other (Fig. 3). The CONSORT statement was written mainly for two-group parallel trials, and extensions cover the other designs.^[15]

Crossover trials

In a crossover trial, participants are randomized to a sequence of interventions and so act as their own control. Dwan and colleagues describe the design as useful and efficient, and their CONSORT extension adds a modified flowchart and baseline table.^[15]

Factorial trials

A factorial trial assesses two or more interventions in the same set of participants. Kahan and colleagues ask authors to report why the design was chosen, whether an interaction was hypothesized and, for each main comparison, the estimated interaction effect and its precision.^[16]

Cluster randomized trials

Cluster randomized trials assign intact groups, such as clinics, to the interventions. Hemming and colleagues show that intracluster correlation gives diminishing returns in power and precision as clusters grow, so the number of clusters and the cluster size should be set together.^[17]

Ivers and colleagues reviewed 300 cluster randomized trials published from 2000 to 2008. Reporting improved on five of 14 criteria after the 2004 CONSORT cluster extension, including identification as cluster randomized and the number of clusters randomized.^[18]

Split-body and other within-person trials

Within-person trials compare interventions applied to two or more body sites of the same participant, as in split-body designs where randomization decides which side receives which intervention. Pandis and colleagues note that these trials are most common in ophthalmology, dentistry and dermatology.^[19]

Because each comparison is made within a person, the design is efficient. The CONSORT within-person extension extends 16 checklist items and introduces a modified flowchart and baseline table.^[19]

Sample size, primary outcome and registration are fixed before enrollment

The primary outcome is the outcome of greatest importance specified in the protocol, and federal regulation notes that it is usually the one used in the power calculation.^[20] SPIRIT 2025 sets out 34 minimum items for a trial protocol, with a new open science section.^[21]

Charles and colleagues reviewed 215 two-arm parallel trials and found that 43% did not report all the parameters needed for the sample size calculation. Only 34% reported all the data, calculated accurately and used accurate assumptions for the control group.^[22]

Trial registration

Registration makes the design and primary outcome public before results exist. The International Committee of Medical Journal Editors announced in 2004 that member journals would require registration in a public registry, and from 2005 trials had to register before enrollment to be published in those journals.^[23][24]

In the United States, 42 CFR Part 11 sets requirements for submitting registration and results information for applicable clinical trials to ClinicalTrials.gov, the registry and results database established by the National Library of Medicine.^[20] The NIH defines a clinical trial as a study in which participants are prospectively assigned to one or more interventions to evaluate their effects on health-related outcomes.^[25]

Zarin and colleagues found that 61% of a sample of registered outcome measures lacked specificity about the metric used in the planned analysis.^[26] A precise registry entry names the measure, the time point and the analysis metric.^[21][26]

Comparing the registry with the report

Chan and colleagues compared protocols with published articles for 102 trials and found that 62% had at least one primary outcome changed, introduced or omitted.^[27] Mathieu and colleagues found discrepancies between registered and published outcomes in 31% of adequately registered trials.^[24]

The COMPare project assessed 67 trials in five major journals against their protocols or registry entries, and 58 of them needed a correction letter.^[28] Any reader can repeat this comparison by opening the trial record on ClinicalTrials.gov.^[20]

Analysis by assigned group preserves the randomized comparison

Intention-to-treat analysis, also called analysis by assigned group, includes every randomized participant in the group to which they were allocated. Schulz and Grimes state that in principle no exclusions after randomization are allowed in the primary analysis.^[5]

Exclusions before randomization leave the comparison unbiased, though they can limit generalizability. Per-protocol analyses keep only participants who followed the protocol, and Schulz and Grimes ask that they be described as secondary, non-randomized comparisons.^[5]

Hollis and Campbell surveyed trial reports published in 1997 in four general medical journals. Of these, 48% mentioned intention-to-treat analysis, the approach was often inadequately described and applied, and 75% of trials had some missing data on the primary outcome.^[29]

Estimands state the question precisely

The ICH E9(R1) addendum, issued by FDA as guidance, presents a structured framework for describing the effect of interest that a clinical trial should address.^[30] Kahan and colleagues explain that estimands clarify the exact research question and align study design, data collection and estimation methods with it.^[31]

CONSORT 2025 defines the complete report of a randomized controlled trial

The CONSORT 2025 statement, published by Hopewell and colleagues, consists of a 30-item checklist and a diagram of participant flow through the trial (Fig. 4). It updates CONSORT 2010 after a three-round Delphi survey of 317 participants and a consensus meeting of 30 experts.^[1]

The update added seven items, revised three, deleted one and introduced a section on open science. The explanation and elaboration document gives the rationale for each item with published examples of good reporting.^[1][2]

The flow diagram counts participants at enrollment, allocation, follow-up and analysis and gives reasons for each exclusion and loss. Schulz and Grimes recommended such a trial profile to show the progress of all randomized participants.^[1][5]

Common weaknesses readers should spot

Meta-epidemiological research points to a short list of features linked to exaggerated effect estimates, with the largest average bias in trials of subjective outcomes.^[11] Each item below maps to the CONSORT 2025 checklist.^[1]

• A sequence generation method left undescribed, or a systematic, non-random method of allocation.^[3][10]
• No description of the allocation concealment mechanism.^[4][9]
• Blinding described only as "double blind", with no statement of who was blinded.^[8][12]
• A primary outcome that differs from the registry entry or protocol.^[27][28]
• Registration dated after the trial was completed.^[24]
• Participants excluded after randomization, or flow diagram counts that fail to reconcile.^[5]
• A sample size calculation with missing parameters.^[22]
• Stratified or minimized allocation analyzed without the balancing factors.^[6]

Where to go from here

The hierarchy of evidence reference places the randomized controlled trial among other study designs, and the sham and placebo controls reference covers comparator arms for procedure-based research. The bias assessment reference applies these checks domain by domain, and the systematic reviews and meta-analysis reference shows how trials are pooled.

The clinical trial phases reference explains how trials are staged, and the exosome clinical trials and remestemcel-L references show these methods in the regulatory record. The clinic launch guide to reading the evidence, the extracellular vesicle potency assay reference and our quality references carry them into sourcing decisions, and our team is glad to discuss any of these methods.